Chemistry:Crinecerfont
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | SSR-125543 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H28ClFN2OS |
| Molar mass | 483.04 g·mol−1 |
Crinecerfont is a corticotropin-releasing factor type 1 receptor (CRF1R) antagonist developed to treat classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD). It is hoped to reduce the need for long-term, high dose glucocorticoid therapy and its associated adverse effects in people with CAH.[1][2][3][4]
References
- ↑ Auchus, Richard J; Sarafoglou, Kyriakie; Fechner, Patricia Y; Vogiatzi, Maria G; Imel, Erik A; Davis, Shanlee M; Giri, Nagdeep; Sturgeon, Julia et al. (17 February 2022). "Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology & Metabolism 107 (3): 801–812. doi:10.1210/clinem/dgab749. PMID 34653252.
- ↑ Newfield, Ron S; Sarafoglou, Kyriakie; Fechner, Patricia Y; Nokoff, Natalie J; Auchus, Richard J; Vogiatzi, Maria G; Jeha, George S; Giri, Nagdeep et al. (18 October 2023). "Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology & Metabolism 108 (11): 2871–2878. doi:10.1210/clinem/dgad270. PMID 37216921.
- ↑ Auchus, Richard J; Sarafoglou, Kyriakie; Fechner, Patricia Y; Vogiatzi, Maria; Giri, Nagdeep; Roberts, Eiry; Sturgeon, Julia; Farber, Robert (8 May 2020). "OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study". Journal of the Endocrine Society 4 (Supplement_1). doi:10.1210/jendso/bvaa046.221.
- ↑ Auchus, Richard; Chan, Jean; Farber, Robert; Fechner, Patricia; Giri, Nagdeep; Nokoff, Natalie; Roberts, Eiry; Sarafoglou, Kyriakie et al. (1 November 2022). "OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia". Journal of the Endocrine Society 6 (Supplement_1): A618. doi:10.1210/jendso/bvac150.1281.
 |  |
